GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has developed its Grabody-B platform to target the insulin-like growth factor 1 receptor (IGF1R) in order to help transport drugs for neurodegenerative disease over the notoriously tricky barrier and into the brain. Source: Fierce Biotech 7/4/2025